A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.

doi:10.1038/s41379-020-00664-y

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Feb 2021

Huang Richard S P, Haberberger James, Severson Eric, Duncan Daniel L, Hemmerich Amanda, Edgerly Claire, Ferguson Naomi Lynn, Williams Erik, Elvin Julia, Vergilio Jo-Anne, Killian Jonathan Keith, Lin Douglas I, Tse Julie, Hiemenz Matthew, Owens Clarence, Danziger Natalie, Hegde Priti S, Venstrom Jeffrey, Alexander Brian, Ross Jeffrey S, Ramkissoon Shakti H

Abstract excerpt

PD-L1 immunohistochemistry (IHC) currently has the most Food and Drug Administration (FDA) approvals as a companion diagnostic (CDx) for immunotherapies in specific tumor types; however, multiple other immunotherapy biomarkers exist. We performed this study to examine and report the prevalence of PD-L1 expression in a wide variety of tumor types and examine its relationship to microsatellite instability (MSI),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Cancer Immunotherapy and Biomarkers

Share to Gene Amplification

Share to Immunohistochemistry

Share to Microsatellite Instability

Share to Mutation

Share to Neoplasms

Source

Open in PubMed

Identifiers

PMID: 32884129
DOI: 10.1038/s41379-020-00664-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.PMID 32884129Read ↗

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.Semantic proximity Read ↗

Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.Semantic proximity Read ↗

PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy.Semantic proximity Read ↗

PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability ScoreSemantic proximity Read ↗

Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.Semantic proximity Read ↗

Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression.Semantic proximity Read ↗

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.Semantic proximity Read ↗

Large-Scale Meta-Analysis of Potential Biomarkers for Treatment Response to Anti-PD-1/PD-L1 Immune Checkpoint InhibitorsSemantic proximity Read ↗

Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.Semantic proximity Read ↗

Prognostic value and immunological role of PD-L1 gene in pan-cancerSemantic proximity Read ↗

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.Semantic proximity Read ↗

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.